Aquestive Therapeutics, Inc. $AQST Position Boosted by Profund Advisors LLC

Profund Advisors LLC raised its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 497.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 195,758 shares of the company’s stock after purchasing an additional 163,019 shares during the period. Profund Advisors LLC’s holdings in Aquestive Therapeutics were worth $906,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of AQST. ADAR1 Capital Management LLC raised its stake in Aquestive Therapeutics by 103.9% during the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 264,000 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in Aquestive Therapeutics in the first quarter valued at approximately $42,000. Legal & General Group Plc acquired a new position in shares of Aquestive Therapeutics during the second quarter worth $44,000. Wealthfront Advisers LLC acquired a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at $44,000. Finally, Keating Financial Advisory Services Inc. bought a new stake in Aquestive Therapeutics during the 2nd quarter worth $52,000. Institutional investors own 32.45% of the company’s stock.

Insider Buying and Selling

In other Aquestive Therapeutics news, insider Sherry Korczynski sold 8,750 shares of Aquestive Therapeutics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the transaction, the insider owned 235,689 shares in the company, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $4.22, for a total value of $105,500.00. Following the transaction, the chief executive officer directly owned 627,317 shares in the company, valued at approximately $2,647,277.74. The trade was a 3.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 58,750 shares of company stock worth $271,675. 6.81% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AQST. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, October 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aquestive Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.60.

Aquestive Therapeutics Trading Up 2.9%

Shares of AQST stock opened at $3.88 on Wednesday. The business’s 50 day simple moving average is $4.62 and its 200 day simple moving average is $4.20. Aquestive Therapeutics, Inc. has a one year low of $2.93 and a one year high of $6.85.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $7.56 million during the quarter, compared to analysts’ expectations of $11.02 million. As a group, equities analysts anticipate that Aquestive Therapeutics, Inc. will post -0.50 EPS for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.